Immune regulatory effects of panobinostat in patients with Hodgkin lymphoma through modulation of serum cytokine levels and T-cell PD1 expression
Yasuhiro Oki(Unknown), Anas Younes(Intercept Pharmaceuticals (United States)), Bastian von Tresckow(University of Cologne), Mark Kirschbaum(Cyclacel Pharmaceuticals (United States)), Patrick B. Johnston(Mayo Clinic in Arizona), Anna Sureda(Institut d'Investigació Biomédica de Bellvitge), Pier Luigi Zinzani(Istituto di Ematologia di Bologna), Simon J. Harrison(Peter MacCallum Cancer Centre), Angela Shen(Unknown), Dina Ben‐Yehuda(Hebrew University of Jerusalem), J. Zhang(The University of Texas MD Anderson Cancer Center), Daniela Buglio(The University of Texas MD Anderson Cancer Center), Shouhao Zhou(Pennsylvania State University), Y Ying(The University of Texas MD Anderson Cancer Center), H. Miles Prince(Peter MacCallum Cancer Centre)
Cited by 61
Related Papers
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
|New England Journal of Medicine|2014|1.1k
Guidelines for the Management of Pediatric and Adult Tumor Lysis Syndrome: An Evidence-Based Review
|Journal of Clinical Oncology|2008|794